|Chemical and physical data|
|Molar mass||1047.21 g/mol|
|3D model (JSmol)|
|(what is this?)|
Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.
- Pasireotide | C58H66N10O9 - PubChem http://pubchem.ncbi.nlm.nih.gov/compound/Pasireotide
- Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
- "Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease". Retrieved 2012-07-08.
- Mancini, Tatiana; Porcelli, Teresa; Giustina, Andrea (2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. PMC . PMID 21063461. doi:10.2147/TCRM.S12952.
- EMEA Approval for Pasireotide
- "FDA Approves Pasireotide for Cushing's Disease".
- Tucker, Miriam E. FDA Approves Pasireotide for Treating Acromegaly, Medscape, December 17, 2014, Retrieved 2015-08-21
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|